In the tropical heart of Hainan Province, the Boao Lecheng International Medical Tourism Pilot Zone is redefining China’s healthcare landscape. Once underdeveloped farmland, the zone has transformed into a beacon of medical innovation since its 2013 launch, now attracting global attention for breakthroughs in rare disease therapies and biomedical research.
The island-wide special customs operations initiated in December 2025 under the Hainan Free Trade Port (FTP) framework have accelerated this growth. Patients like 34-year-old Li Wei, who accessed a groundbreaking gene therapy for a rare immune disorder last month, exemplify the tangible impact. "Without Lecheng’s policies, this treatment would have taken years to reach me," he shared.
Over 200 international medical technologies and drugs have been fast-tracked through Lecheng’s "first import, then register" policy since 2021. This year alone, 15 new clinical trials for cancer immunotherapies have launched, drawing partnerships from European and Asian biotech firms. Dr. Zhang Mei, a researcher at the zone’s innovation center, noted, "We’re bridging global medical advancements with domestic needs faster than ever.\p>
As the FTP reforms deepen, Lecheng aims to expand its telemedicine network across Southeast Asia by late 2026, positioning Hainan as a nexus for medical tourism and cross-border healthcare collaboration.
